Cargando…
Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer
PURPOSE: To evaluate the sensitivity and specificity of different screening modalities in women with a family history of breast cancer. METHODS: Our blinded, prospective, comparative cohort analysis included three types of screening, mammography, ultrasound, and clinical breast examination once per...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842249/ https://www.ncbi.nlm.nih.gov/pubmed/29318406 http://dx.doi.org/10.1007/s10549-017-4639-0 |
_version_ | 1783304860824764416 |
---|---|
author | Liljegren, Annelie von Wachenfeldt, Anna Azavedo, Edward Eloranta, Sandra Grundström, Helene Ståhlbom, Anne Kinhult Sundbom, Ann Sundén, Per Svane, Gunilla Ulitzsch, Dieter Arver, Brita |
author_facet | Liljegren, Annelie von Wachenfeldt, Anna Azavedo, Edward Eloranta, Sandra Grundström, Helene Ståhlbom, Anne Kinhult Sundbom, Ann Sundén, Per Svane, Gunilla Ulitzsch, Dieter Arver, Brita |
author_sort | Liljegren, Annelie |
collection | PubMed |
description | PURPOSE: To evaluate the sensitivity and specificity of different screening modalities in women with a family history of breast cancer. METHODS: Our blinded, prospective, comparative cohort analysis included three types of screening, mammography, ultrasound, and clinical breast examination once per year for 6 years. Eligible patients for this study were healthy women with ≥ 17% lifetime risk of breast cancer or with a mutation in BRCA1 or BRCA2. RESULTS: A total of 632 women were screened between 2002 and 2012 (each for 6 years). During the study, 30 women were diagnosed with breast cancer, with 10 of these diagnoses occurring between screening visits, and six of the 10 diagnosed women were gene carriers. The clinical presentation for the women diagnosed with breast cancer was followed until 2017. No consistent patterns for the diagnostic capacity of the different screening modalities were found, although mammography showed low sensitivity, whereas ultrasound showed better sensitivity in three of the six rounds. The specificity was high in mammography and improved in ultrasound over time. Most importantly, clinical breast examination provided no additional information toward the diagnosis of breast cancer. CONCLUSION: Neither mammography nor ultrasound performed yearly were sensitive enough as standalone modalities, although high specificity was confirmed. Our findings indicate that high risk (> 29% life time risk) individuals and gene carriers can be screened biannually, using the same protocol as used in mutation carriers. Our results also suggest that low-risk groups (< 20%) may continue to be referred to population mammography screening program, while clinical breast examination may be omitted in all risk groups, and could be optional in gene carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-017-4639-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5842249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-58422492018-03-19 Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer Liljegren, Annelie von Wachenfeldt, Anna Azavedo, Edward Eloranta, Sandra Grundström, Helene Ståhlbom, Anne Kinhult Sundbom, Ann Sundén, Per Svane, Gunilla Ulitzsch, Dieter Arver, Brita Breast Cancer Res Treat Clinical Trial PURPOSE: To evaluate the sensitivity and specificity of different screening modalities in women with a family history of breast cancer. METHODS: Our blinded, prospective, comparative cohort analysis included three types of screening, mammography, ultrasound, and clinical breast examination once per year for 6 years. Eligible patients for this study were healthy women with ≥ 17% lifetime risk of breast cancer or with a mutation in BRCA1 or BRCA2. RESULTS: A total of 632 women were screened between 2002 and 2012 (each for 6 years). During the study, 30 women were diagnosed with breast cancer, with 10 of these diagnoses occurring between screening visits, and six of the 10 diagnosed women were gene carriers. The clinical presentation for the women diagnosed with breast cancer was followed until 2017. No consistent patterns for the diagnostic capacity of the different screening modalities were found, although mammography showed low sensitivity, whereas ultrasound showed better sensitivity in three of the six rounds. The specificity was high in mammography and improved in ultrasound over time. Most importantly, clinical breast examination provided no additional information toward the diagnosis of breast cancer. CONCLUSION: Neither mammography nor ultrasound performed yearly were sensitive enough as standalone modalities, although high specificity was confirmed. Our findings indicate that high risk (> 29% life time risk) individuals and gene carriers can be screened biannually, using the same protocol as used in mutation carriers. Our results also suggest that low-risk groups (< 20%) may continue to be referred to population mammography screening program, while clinical breast examination may be omitted in all risk groups, and could be optional in gene carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-017-4639-0) contains supplementary material, which is available to authorized users. Springer US 2018-01-09 2018 /pmc/articles/PMC5842249/ /pubmed/29318406 http://dx.doi.org/10.1007/s10549-017-4639-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Liljegren, Annelie von Wachenfeldt, Anna Azavedo, Edward Eloranta, Sandra Grundström, Helene Ståhlbom, Anne Kinhult Sundbom, Ann Sundén, Per Svane, Gunilla Ulitzsch, Dieter Arver, Brita Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title | Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title_full | Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title_fullStr | Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title_full_unstemmed | Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title_short | Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer |
title_sort | prospective blinded surveillance screening of swedish women with increased hereditary risk of breast cancer |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842249/ https://www.ncbi.nlm.nih.gov/pubmed/29318406 http://dx.doi.org/10.1007/s10549-017-4639-0 |
work_keys_str_mv | AT liljegrenannelie prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT vonwachenfeldtanna prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT azavedoedward prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT elorantasandra prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT grundstromhelene prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT stahlbomannekinhult prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT sundbomann prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT sundenper prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT svanegunilla prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT ulitzschdieter prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer AT arverbrita prospectiveblindedsurveillancescreeningofswedishwomenwithincreasedhereditaryriskofbreastcancer |